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Abstract
Backgrounds
We investigated the prognostic impact of antithrombotic regimens at 1-year after percutane-
ous coronary intervention (PCI) among patients with atrial fibrillation (AF).
Method and results
A total of 13,278 AF patients who underwent PCI from 2009 to 2013 were selected from
Korean National Health Insurance Service database. Patients were categorized by antith-
rombotic regimens at 1-year after PCI: (1) OAC with or without single antiplatelet (OAC
±SAPT); (2) triple therapy (TT) and (3) antiplatelets (APT) only. After propensity score
matching, composite ischaemia (death, myocardial infarction, and stroke), composite bleed-
ing (intracranial hemorrhage and gastrointestinal bleeding), and a composite clinical out-
come (composite ischaemia and bleeding) were compared. Of total population, 1,100
(8.3%), 746 (5.6%), and 11,432 (86.1%) were treated with OAC±SAPT, TT, and APT only,
respectively. Compared to OAC±SAPT group, the TT group had significantly higher risk of
the composite clinical outcome (hazard ratio [HR] 1.46, 95% confidence interval [CI] 1.00–
2.13) attributed to a higher trend in both ischaemia (HR 1.63, 95% CI 0.99–2.67) and bleed-
ing (HR 1.22, 95% CI 0.69–2.13). The APT only group showed a higher risk of ischaemia
(HR 1.85, 95% CI 1.25–2.74), despite a lower risk of bleeding (HR 0.55, 95% CI 0.32–0.94)
compared to OAC±SAPT group.
Conclusions
OAC±SAPT was associated with better clinical outcomes compared to TT or APT only treat-
ments, beyond 1-year after PCI among Asians with AF.
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Introduction
Patients with atrial fibrillation (AF) at moderate to high risk of stroke are recommended for
stroke prevention with oral anticoagulants (OAC) and for those who underwent percutaneous
coronary intervention (PCI), combination antithrombotic therapy with OAC and antiplatelets
(APT) is required [1–3]. However, previous studies reported an under-prescription of OAC in
patients with AF after PCI, especially among the Asian population [4–7]. This relates to con-
cerns that Asians with AF tend to have a higher risk of stroke and more seriously, intracranial
hemorrhage when compared to non-Asians [8]. Also, those on OAC were associated with a
higher rate of major bleeding than non-Asians [9]. It is therefore important to determine the
optimal regimen and duration of antithrombotic therapy among the Asian patients with AF
after PCI. Recently, the Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON
and Coronary stEnt (OAC-ALONE) trial was conducted comparing the efficacy and safety
benefit of OAC alone versus dual therapy (OAC plus SAPT) among Asian patients with AF
beyond 1-year after PCI [10]. However, the study was underpowered for the primary outcome
due to early trial termination related to delayed enrollment of study population. In real-world
clinical practice, the optimal antithrombotic therapy regime in the period after PCI among
patients with AF is important given the underuse of OAC [9] and early discontinuation of
APT [11]. Therefore, we sought to investigate the treatment patterns and the prognostic
impact of different antithrombotic therapy regimes on ischaemic and bleeding events, at
1-year after PCI among patients with AF.
Methods
Study population and clinical data were derived from the National Health Insurance Service
(NHIS) claim database of Korean population which includes inpatient and outpatient medical
records, diagnostic codes and claims for the procedure or medication prescription [12, 13].
For the current study, a total of 226,118 patients who had PCI with coronary stent implanta-
tion between 2009 to 2013 were screened for inclusion (S1 Fig). Procedure codes for PCI and
coronary stent implantation (M6561, M6562, M6563, and M6564) were used as PCI events. Of
them, we excluded patients with death, myocardial infarction (MI) or PCI procedure within 1
year after the index procedure, those without AF diagnosis, those with incomplete prescription
records or no antithrombotic therapy at 1-year after PCI. Patients with AF were defined as
those with diagnostic codes for AF (International Classification of Disease, Tenth Revision,
Clinical Modification [ICD-10-CM] I480–I484 and I489) at�1 hospitalization or at�2 outpa-
tient clinics. To exclude patients with AF associated with valvular heart disease, those with
diagnostic codes for mitral stenosis (I50, I52, and I59) or mechanical heart valves (Z952–Z954)
were excluded. Finally, a total of 13,278 patients with non-valvular AF and complete prescrip-
tion records were included for analysis. The definitions of comorbidities were summarized in
S1 Table and have been validated in previous studies [5, 14, 15]. In brief, hypertension and dia-
betes mellitus (DM) were defined as diagnostic codes with claims of at least one prescription
of antihypertensive or antidiabetic drug respectively. Patients with previous history of conges-
tive heart failure (CHF), stroke or systemic thromboembolism, myocardial infarction (MI),
peripheral artery disease (PAD), and intracranial hemorrhage (ICH) were defined based on
ICD-10-CM codes. Individual stroke risk was estimated by the CHA2DS2-VASc score. This
study was approved by the Institutional Review Board of Seoul National University Hospital
(1706-160-863). The informed consent was waived by the review board because the identifica-
tion number of each patient in the NHIS database is de-identified and encrypted to protect
patient privacy.
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Inpatient and outpatient records for antithrombotic therapy including aspirin, clopidogrel,
vitamin K antagonists (VKA), and non-vitamin K antagonist oral anticoagulants (NOAC)
were retrieved within 3-months windows before and after the 1-year follow-up period from
the index PCI event. New generation P2Y12 inhibitors including prasugrel and ticagrelor were
not considered as APT because they were not widely available in Korea during the study
period. To reduce misclassification in the treatment group, patients with claims for at least
3-month prescription of antithrombotic therapy (OAC or APT) within the window periods
were considered as those who were on treatment. For further comparison of clinical outcomes,
patients were categorized in to three groups based on prescription regimen of antithrombotic
therapy: OAC monotherapy and OAC + SAPT (OAC ± SAPT), triple therapy (TT, OAC
+ DAPT), and APT only (SAPT or DAPT).
For ischaemic risks, the composite ischaemic outcome was defined including MI, ischaemic
stroke or death. For bleeding risk, the occurrence of ICH or gastrointestinal bleeding (GIB)
were combined into composite bleeding outcome. Also, a composite clinical outcome was
defined comprising composite ischaemic and bleeding outcomes. The detailed definition of
clinical outcomes (MI, stroke, ICH and GIB) was summarized in S2 Table and was validated
in previous study [16]. In brief, MI and GIB were defined as primary discharge diagnostic
codes at hospitalization. Stroke and ICH were defined as primary discharge diagnostic codes
and claims of brain imaging studies such as computed tomography or magnetic resonance
imaging at hospitalization. The index date was defined as the date when the patients had PCI
with stent implantation. Patients were censored at the outcome events or at the end of the
study period (December 31, 2015), whichever comes first.
Baseline characteristics were presented as mean ± standard deviation and numbers with
percentages for continuous variables and categorical variables respectively. The difference
in baseline characteristics between groups was compared using student t test or one-way
ANOVA for continuous variable and chi-square test for categorical variables. Ischaemic,
bleeding and composite clinical outcomes were compared between patients with (1) OAC
and APT only, (2) OAC ± SAPT and TT, and (3) OAC ± SAPT and APT only. For the com-
parison between the groups, we demonstrated a propensity score matching analysis [17].
The propensity score in each comparison was estimated with a logistic regression model
based on the covariates: age, sex, DM, dyslipidemia, CHF, peripheral arterial disease, previ-
ous myocardial infarction, previous history of PCI, previous history of ICH or stroke, and
CHA2DS2-VASc score. In each comparison, patients were matched with 1:1 fashion using
the greedy nearest-neighbor method with a caliper of 0.01 of the propensity score [17].
Post-matching balance of baseline characteristics between the groups was assessed using the
absolute standardized difference (ASD), which the value less than 0.1 indicates a negligible
difference [18]. We also performed sensitivity analysis using three different multivariable
Cox hazard regression model based on the covariates (Model 1: age and sex; Model 2: age,
sex, and CHA2DS2-VASc score; Model 3: age, sex, CHA2DS2-VASc score, DM, hyperten-
sion, dyslipidemia, previous history of CHF, stroke or systemic thromboembolism, MI,
PAD, PCI, and ICH). Statistical significance was set at two-tailed p values of <0.05. Statisti-
cal analyses were performed using the SAS software version 9.3 (SAS Institute, Cary, NC,
USA).
Results
Of total population (N = 13,278), 1,846 (13.9%) received OAC at 1-year after PCI. Patients
with OAC were older, had a higher prevalence of male, DM, CHF, previous history of stroke
and a higher CHA2DS2-VASc score compared to those with APT only (Table 1). After 1:1
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propensity score matching, the difference in baseline characteristics was well balanced (ASD
<0.1) and total 1,846 pairs of patients were included for analysis. The mean follow-up duration
was 2.5 years. There was no significant difference regarding composite clinical outcome
between patients with OAC and APT only (hazard ratio [HR] 1.08, confidence interval [CI]
0.86–1.35) (Fig 1A, Table 2). Those with APT only had a higher risk of composite ischaemic
events (HR 1.45, 95% CI 1.10–1.90) (Fig 1B) with a lower risk of composite bleeding (HR 0.57,
95% CI 0.39–0.85) (Fig 1C). Similar results were found by sensitivity analysis using multivari-
able Cox regression analysis (S3 Table).
Table 1. Baseline characteristics of study population according to OAC prescription at 1-year after PCI.
Crude population PS Matched population
OAC ± APT APT only p-value OAC ± APT APT only ASD
(N = 1,846) (N = 11,432) (N = 1,846) (N = 1,846)
Age, years 68.9 ± 8.9 68.2 ± 10.2 0.005 68.9 ± 8.9 69.0 ± 9.4 0.012
Age (� 65) 1,349 (73.1) 7,806 (68.3) <0.001 1,349 (73.1) 1,355 (73.4) 0.007
Male 1,288 (69.8) 7,218 (63.1) <0.001 1,288 (69.8) 1,292 (70.0) 0.005
Diabetes mellitus 723 (39.2) 4,166 (36.4) 0.024 723 (39.2) 745 (40.4) 0.024
Hypertension 1,639 (88.8) 10,080 (88.2) 0.448 1,639 (88.8) 1,655 (89.7) 0.028
Dyslipidemia 1,501 (81.3) 9,677 (84.7) <0.001 1,501 (81.3) 1,513 (82.0) 0.017
Congestive heart failure 870 (47.1) 4,167 (36.5) <0.001 870 (47.1) 887 (48.1) 0.018
Peripheral arterial disease 382 (20.7) 2,773 (24.3) <0.001 382 (20.7) 376 (20.4) 0.008
Previous myocardial infarction 480 (26.0) 3,086 (27.0) 0.372 480 (26.0) 499 (27.0) 0.023
Previous PCI 189 (10.2) 1,613 (14.1) <0.001 189 (10.2) 164 (8.9) 0.046
Previous ICH 11 (0.6) 107 (0.9) 0.149 11 (0.6) 11 (0.6) <0.001
Previous stroke 673 (36.5) 2,230 (19.5) <0.001 673 (36.5) 649 (35.2) 0.027
CHA2DS2-VASc score 4.75 ± 1.81 4.34 ± 1.82 <0.001 4.75 ± 1.81 4.76 ± 1.83 0.004
0 3 (0.2) 63 (0.6) 3 (0.16) 2 (0.11)
1 41 (2.2) 481 (4.2) 41 (2.22) 40 (2.17)
� 2 1,802 (97.6) 10,888 (95.2) 1,802 (97.6) 1,804 (97.7)
Antithrombotic therapy
Triple therapy 746 (40.4) - 746 (40.4) -
Warfarin-based 740 (40.1) - 740 (40.1) -
NOAC-based 6 (0.3) - 6 (0.3) -
OAC + SAPT 919 (49.8) - 919 (49.8) -
Warfarin + Aspirin 390 (21.1) - 390 (21.1) -
Warfarin + Clopidogrel 505 (27.4) - 505 (27.4) -
NOAC + Aspirin 9 (0.5) - 9 (0.5) -
NOAC + Clopidogrel 15 (0.8) - 15 (0.8) -
OAC monotherapy 181 (9.8) - 181 (9.8) -
Warfarin 164 (8.9) - 164 (8.9) -
NOAC 17 (0.9) - 17 (0.9) -
DAPT - 7,978 (69.8) - 1,248 (67.6)
SAPT - 3,454 (30.2) - 598 (32.4)
Aspirin - 1,643 (14.4) - 247 (13.4)
Clopidogrel - 1,811 (15.8) - 351 (19.0)
The numbers are presented as mean ± standard deviation or numbers (percentage) otherwise mentioned.
Abbreviation: ASD, absolute standardized difference; APT, antiplatelets; ICH, intracranial hemorrhage; NOAC, non-Vitamin K antagonist oral anticoagulants, OAC,
oral anticoagulants; PCI, percutaneous coronary intervention; PS, propensity score.
https://doi.org/10.1371/journal.pone.0240161.t001
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Regarding antithrombotic regimens, 181 (1.4%), 919 (6.9%), 746 (5.6%), and 11,432
(86.1%) received OAC monotherapy, OAC + SAPT, TT, and APT only, respectively at 1-year
after PCI. (S4 Table) Compared to patients with OAC±SAPT, those with TT were younger and
had a higher prevalence of previous history of MI, and PCI event, whereas a lower prevalence
of previous history of stroke and CHA2DS2-VASc score. The baseline characteristics were well
balanced between groups after 1:1 propensity score matching (ASD <0.1) resulting in 732
pairs of patients for analysis (Table 3). compared to patients with APT only, those with OAC
±SAPT were older and had a higher prevalence of DM, hypertension, CHF, stroke and higher
CHA2DS2-VASc, whereas a lower prevalence of previous MI, PAD and PCI event. After pro-
pensity score matching, the baseline characteristics was well balanced (ASD <0.1) and total
1,100 pairs of patients were included (Table 3).
Patients with TT showed a significantly higher risk of the composite clinical outcome (HR
1.46, 95% CI 1.00–2.13) (Fig 2A, Table 4) compared to those with OAC±SAPT. This result is
Fig 1. Ischaemic/bleeding risk in patients with AF according to OAC prescription at 1 year after PCI. Cumulative risk of composite clinical
outcome (Fig 1A), composite ischaemia (Fig 1B), and composite bleeding (Fig 1C) was compared between patients with OAC and APT only.
AF = atrial fibrillation, APT = antiplatelets, GI = gastrointestinal, ICH = intracranial hemorrhage, MI = myocardial infarction, OAC = oral
anticoagulants, PCI = percutaneous coronary intervention.
https://doi.org/10.1371/journal.pone.0240161.g001
Table 2. Clinical outcome according to OAC prescription at 1-year after PCI.
OAC ± APT (N = 1,846) APT only (N = 1,846)
Event, N Person-year Rate� Event, N Person-year Rate� HR (95% CI)
Composite Clinical Outcome 143 3972.4 3.6 165 4287.4 3.8 1.08 (0.86–1.35)
Composite Ischaemic Outcome 84 4063.4 2.1 129 4344.7 3.0 1.45 (1.10–1.90)
Death 17 4157.5 0.4 83 4416.2 1.9 4.63 (2.75–7.81)
Myocardial Infarction 23 4129.6 0.6 23 4383.6 0.5 0.95 (0.53–1.69)
Stroke 66 4091.3 1.6 80 4377.4 1.8 1.14 (0.82–1.58)
Composite Bleeding Outcome 64 4059.6 1.6 39 4357.7 0.9 0.57 (0.39–0.85)
ICH 14 4132.5 0.3 13 4403.2 0.3 0.88 (0.41–1.87)
Gastrointestinal Bleeding 56 4081.5 1.4 31 4370.7 0.7 0.52 (0.34–0.81)
Abbreviation: APT, antiplatelets; CI, confidence interval; HR, hazard ratio; ICH, intracranial hemorrhage; OAC, oral anticoagulants; PCI, percutaneous coronary
intervention.
�100-person years.
https://doi.org/10.1371/journal.pone.0240161.t002
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attributed by a nonsignificant trend towards a higher risk of composite ischaemic events (HR
1.63, 95% CI 0.99–2.67) (Fig 2B) and composite bleeding (HR 1.22, 95% CI 0.69–2.13) (Fig
2C) in patients with TT compared to those with OAC±SAPT. The results were consistent in
the sensitivity analysis using multivariable Cox regression analysis. (S5 Table) Patients with
APT only showed a comparable risk of composite clinical outcome compared to those with
OAC±SAPT (HR 1.24, 95% CI 0.91–1.69) (Fig 2D, Table 4). This result was driven by a higher
risk of composite ischaemia in patients with APT only compare to those with OAC±SAPT
(HR 1.85, 95% CI 1.25–2.74) (Fig 2E), which was compensated by a lower risk of composite
bleeding (HR 0.55, 95% CI 0.32–0.94) (Fig 2F). Similar trends were found for patients with
OAC+SAPT compared to those with APT only (S6 Table). Sensitivity analysis also showed
consistent results (S5 Table).
Discussion
The current study is the largest nationwide study investigating prescription patterns of antith-
rombotic therapy in Asian patients with AF at 1-year after PCI and their prognostic impact on
long-term ischaemic and bleeding risk. Our principal findings are as follows: (i) most patients
(86.1%) did not receive OAC at 1-year after PCI though most of them were clinically indicated
for anticoagulation (95.2% with CHA2DS2-VASc score�2); (ii) only a minority of patients
(1.4%) received OAC monotherapy at 1-year after PCI, different from guideline recommenda-
tions; (3) patients with OAC were associated with a lower risk of composite ischaemic events
despite a higher bleeding risk compared to those with APT only; and (iv) patients with APT
only were associated with a significantly higher risk of the composite ischaemic outcome and a
lower risk of the composite bleeding outcome, when compared to those with OAC±SAPT.
Table 3. Characteristics of propensity score matched population according to antithrombotic regimen at 1-year after PCI.
OAC ± SAPT TT ASD OAC ± SAPT APT only ASD
(N = 732) (N = 732) (N = 1,100) (N = 1,100)
Age, years 68.5 ± 8.9 68.2 ± 9.4 0.032 69.5 ± 8.4 69.7 ± 8.6 0.017
Age (� 65) 518 (70.8) 516 (70.5) 0.006 831 (75.6) 847 (77.0) 0.034
Male 499 (68.1) 522 (71.3) 0.068 755 (68.6) 755 (68.6) <0.001
Diabetes mellitus 295 (40.3) 284 (38.8) 0.031 434 (39.5) 429 (39.0) 0.009
Hypertension 653 (89.2) 649 (88.7) 0.017 978 (88.9) 1,004 (91.3) 0.079
Dyslipidemia 591 (80.7) 593 (81.0) 0.007 900 (81.8) 918 (83.5) 0.043
Congestive heart failure 352 (48.1) 352 (48.1) <0.001 512 (46.6) 527 (47.9) 0.027
Peripheral arterial disease 153 (20.9) 159 (21.7) 0.020 221 (20.1) 213 (19.4) 0.018
Previous myocardial infarction 198 (27.1) 204 (27.9) 0.018 271 (24.6) 263 (23.9) 0.017
Previous PCI 76 (10.4) 80 (10.9) 0.018 107 (9.7) 91 (8.3) 0.051
Previous ICH 3 (0.4) 3 (0.4) <0.001 8 (0.7) 7 (0.6) 0.011
Previous stroke 237 (32.4) 246 (33.6) 0.026 423 (38.5) 406 (36.9) 0.032
CHA2DS2-VASc score 4.81 ± 1.81 4.7 ± 1.78 0.061 4.79 ± 1.82 4.78 ± 1.81 0.006
0 1 (0.1) 1 (0.1) 2 (0.18) 2 (0.2)
1 18 (2.5) 18 (2.5) 21 (1.9) 20 (1.8)
� 2 713 (97.4) 713 (97.4) 1,077 (97.9) 1,078 (98.0)
The numbers are presented as mean ± standard deviation or numbers (percentage) otherwise mentioned.
Abbreviation: ASD, absolute standardized difference; APT, antiplatelets; ICH, intracranial hemorrhage; NOAC, non-Vitamin K antagonist oral anticoagulants, OAC,
oral anticoagulants; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; TT, triple therapy.
https://doi.org/10.1371/journal.pone.0240161.t003
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Previous studies had reported under-prescription of OAC among patients with AF beyond
1-year after PCI [17, 18]. In a Danish study reporting antithrombotic therapy among 8,700
patients with AF and stable CAD, more than half of patients (62.7%) had only APT without
OAC at 1-year after PCI, whereas only 950 (10.5%) patients received OAC monotherapy [19].
In a recent Asian study, OAC prescription in AF patients at 1-year after PCI was only 2.2%,
and most of patients were still maintained on aspirin and clopidogrel (96.1% and 76.3%,
respectively) [20]. In line with previous reports, we found that most patients received only
APT without OAC despite their high risk of stroke. Considering that current guidelines rec-
ommending life-long anticoagulation in patients with AF beyond 1-year after PCI, most of
patients in the real world were not in accord with guidelines.
In our results, patients with APT only had a higher prevalence of cardiovascular disease
such as MI, PAD, and previous PCI history which would clinically require long-term APT
therapy. Previously, we reported similar trends in antithrombotic therapy after PCI among the
patients with AF. The prescription rate of TT after PCI was less than 40% in recent 10 years,
whereas most patients received DAPT without OAC. Taken together, our results suggest that
physicians may opt to maintain APT instead of OAC after PCI in patients with AF. This would
often be associated with the clinical ineligibility for OAC treatment such as inadequate inter-
national normalized ratio monitoring or concerns regarding a higher risk of bleeding event
following combination antithrombotic therapy with both OAC and APT [21]. However, as
concomitant history of PAD or CAD significantly increases cardiovascular events in patients
with AF [22], optimized combination antithrombotic therapy is essential for these patients.
Fig 2. Ischaemic/bleeding risk in patients with AF according to antithrombotic therapy at 1 year after PCI. Cumulative risks for ischaemic, bleeding
events, and composite outcome were assessed among patients with TT and APT only compared to those with OAC ± SAPT. AF = atrial fibrillation,
APT = antiplatelets, GI = gastrointestinal, ICH = intracranial hemorrhage, MI = myocardial infarction, OAC = oral anticoagulants, PCI = percutaneous
coronary intervention, SAPT = single antiplatelets, TT = triple therapy.
https://doi.org/10.1371/journal.pone.0240161.g002
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For patients with AF who had PCI with coronary stent implantation, life-long anticoagula-
tion is recommended in guidelines, after a period of combination antithrombotic therapy,
though concomitant SAPT could be considered in those with a high risk of ischaemia, for
example, left main coronary artery disease. We found that among 1,846 patients with AF who
received OAC at 1-year after PCI, 40.4% of these were still maintained on TT; however,
patients on TT showed no clinical benefit compared to those with OAC±SAPT.
Similar results have been reported in non-Asian population. For example, Lamberts et al.
investigated the prognostic relevance of antithrombotic regimens among patients with AF and
stable CAD [19]. Compared to OAC monotherapy, there was no prognostic benefit in reduc-
ing the risk of thromboembolism with combination antithrombotic therapy, but the risk of
bleeding was highest in those with TT.
As the numbers of patients with OAC monotherapy was relatively small (N = 181) com-
pared to previous studies, we could not evaluate the prognostic benefit of OAC monotherapy
compared to other groups. However, this result could be attributed to a higher percentage of
patients who underwent PCI with coronary stent implantation in our study population (100%
vs 32.5%), which generally encourages many Korean physicians to maintain prolonged APT
without OAC beyond 1-year after PCI. Previously, the Optimizing Antithrombotic Care in
Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE), a prospective random-
ized controlled open label trial was conducted comparing the efficacy and safety benefit of
OAC alone versus OAC plus single APT in AF patients beyond 1-year after PCI with coronary
stent implantation [10]. Although no significant differences were observed in primary out-
comes (all-cause death, myocardial infarction, stroke, or system embolism) between groups
(15.7% vs. 13.6% for OAC monotherapy vs. OAC + SAPT; HR 1.16, 95% CI 0.79–1.72; P for
Table 4. Clinical outcome according to antithrombotic therapy at 1-year after PCI.
OAC ± SAPT (N = 732) TT (N = 732)
Event, N Person-year Rate� Event, N Person-year Rate� HR (95% CI)
Composite Clinical Outcome 43 1481.4 2.9 71 1697.5 4.2 1.46 (1.00–2.13)
Composite Ischaemic Outcome 24 1508.3 1.6 45 1739.9 2.6 1.63 (0.99–2.67)
Death 5 1529.5 0.3 3 1804.6 0.2 0.53 (0.13–2.23)
Myocardial Infarction 7 1525.5 0.5 13 1782.6 0.7 1.57 (0.62–3.93)
Stroke 21 1512.3 1.4 37 1762.0 2.1 1.55 (0.90–2.67)
Composite Bleeding Outcome 21 1500.9 1.4 29 1757.2 1.7 1.22 (0.69–2.13)
ICH 6 1521.8 0.4 4 1792.3 0.2 0.60 (0.17–2.13)
Gastrointestinal Bleeding 17 1508.6 1.1 25 1769.4 1.4 1.28 (0.69–2.37)
OAC ± SAPT (N = 1,100) APT only (N = 1,100)
Event, N Person-year Rate� Event, N Person-year Rate� HR (95% CI)
Composite Clinical Outcome 69 2250.9 3.1 94 2521.3 3.7 1.24 (0.91–1.69)
Composite Ischaemic Outcome 37 2297.0 1.6 74 2548.7 2.9 1.85 (1.25–2.74)
Death 13 2326.0 0.6 43 2601.2 1.7 3.03 (1.63–5.63)
Myocardial Infarction 10 2320.2 0.4 19 2571.5 0.7 1.72 (0.80–3.71)
Stroke 28 2302.8 1.2 49 2578.4 1.9 1.61 (1.01–2.56)
Composite Bleeding Outcome 34 2278.2 1.5 21 2573.8 0.8 0.55 (0.32–0.94)
ICH 10 2313.3 0.4 4 2595.8 0.2 0.36 (0.11–1.14)
Gastrointestinal Bleeding 30 2287.8 1.3 18 2579.2 0.7 0.53 (0.30–0.95)
Abbreviation: APT, antiplatelets; CI, confidence interval; HR, hazard ratio; ICH, intracranial hemorrhage; OAC, oral anticoagulants; PCI, percutaneous coronary
intervention; SAPT, single antiplatelet therapy; TT, triple therapy.
�100-person years.
https://doi.org/10.1371/journal.pone.0240161.t004
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superiority = 0.45; P for non-inferiority = 0.20), the study was underpowered as the trial was
prematurely terminated due to delayed enrollment (696 patients in 38 months). Of note that
the median interval between subject enrollment and index PCI procedure was 4.4 to 4.6 years,
but over 85% of patients in both groups still received concomitant aspirin with OAC at base-
line, similar to our results. The addition of SAPT with OAC compared to OAC monotherapy
in patients with AF is questionable, as nearly 30% received bare metal stent and those with left
main coronary stenting was below 7% of the total trial population.
In the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events
(ACTIVE W) trial [23]. OAC was superior to clopidogrel plus aspirin in reducing vascular
events in patients with AF at high risk of stroke, with no difference in major bleeding between
OAC and aspirin-clopidogrel. In patients with CAD, sufficient inhibition of platelet function
by DAPT for at least 6 to 12-months after PCI with drug-eluting stent implantation would suf-
fice [24]. However, the benefit of APT would be limited to an initial period of stabilization of
the coronary lesion with intensive combination antithrombotic therapy beyond which a sus-
tained hypercoagulable status due to AF [25] persists and requires OAC. In the current study,
compared to patients with OAC±SAPT, those with APT only was related to a higher risk of
composite ischaemia and stroke suggesting the importance of prolonged OAC in reducing
thromboembolic risk among patients with AF after PCI.
An increasing risk of fatal bleeding is the major hurdle in combining OAC prescription on
APT therapy [21]. In the current study, the benefit of OAC in reducing the ischaemic risk was
compensated by a higher risk of bleeding events, especially for GI bleeding. The higher bleed-
ing risk in patients with OAC groups compared to those with APT only would be accentuated
by prolonged prescription of APT in these patients, which is inconsistent with guideline rec-
ommendations [1, 2]. Since NOAC has been the primary choice for anticoagulation in AF
management [1–3], growing evidence has shown the clinical benefit of NOAC-based combina-
tion therapy after PCI in AF patients compared with conventional VKA-based triple therapy.
Currently, 4 randomized trials with different types of NOAC have been reported: PIORNEER
AF-PCI (rivaroxaban) [26], RE-DUAL PCI (dabigatran) [27], AUGUSTUS (apixaban) [28],
and ENTRUST-AF PCI (edoxaban) [29]. These trials have confirmed that NOAC-based dual
therapy was superior for bleeding risks and comparable for ischaemic risks as stroke and
adverse cardiovascular events than VKA-based triple therapy. In our result, most of the
patients with OAC had prescribed warfarin, which may attribute to an even higher risk for
bleedings in the OAC group than that would be expected with NOAC. Considering that the
proportions for NOAC are also expected in the long-term antithrombotic therapy after PCI [5,
6], future nationwide studies with extended inclusion period would be valuable demonstrating
the effectiveness and safety of NOAC-based antithrombotic therapy in AF patients beyond
1-year after PCI.
There are several limitations to our study. First, because of the non-randomized design of
the current study, there could be potential confounding factors despite propensity score
matching between groups. Second, we categorized the patients according to the antithrombo-
tic regimen at 1-year after PCI. However, the data regarding the temporal change in antith-
rombotic therapy were not included in our results. Third, as the study population and clinical
data were derived from the NHIS claim database, the information regarding drug compliance
with laboratory results such as INR could not be obtained. Fourth, detailed information on
coronary lesion characteristics including left main coronary disease or multi-vessel disease
and procedural results were not available in the database. Fifth, as the number of patients was
small, we could not assess the prognostic impact of OAC monotherapy related to long-term
ischaemia/bleeding risk in patients with AF after PCI. Last, the data regarding individual risk
PLOS ONE Antithrombotic therapy in AF patients after PCI
PLOS ONE | https://doi.org/10.1371/journal.pone.0240161 October 15, 2020 9 / 12
of bleeding (i.e. HAS-BLED score or previous history of bleeding) were not available in our
database.
Conclusions
OAC prescription was low at 1-year after PCI in patients with AF, and substantial proportion
of them had TT. OAC monotherapy with or without SAPT was associated with better clinical
outcomes compared to TT or APT treatments, beyond 1-year after PCI among Asians with
AF.
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